Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2007 May;11(5):395-406.

Synergy between PPARgamma ligands and platinum-based drugs in cancer.

Author information

1
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Abstract

PPARgamma is a member of the nuclear receptor family for which agonist ligands have antigrowth effects. However, clinical studies using PPARgamma ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARgamma activation with chemotherapeutic agents in current use for specific cancers. We observed a striking synergy between rosiglitazone and platinum-based drugs in several different cancers both in vitro and using transplantable and chemically induced "spontaneous" tumor models. The effect appears to be due in part to PPARgamma-mediated downregulation of metallothioneins, proteins that have been shown to be involved in resistance to platinum-based therapy. These data strongly suggest combining PPARgamma agonists and platinum-based drugs for the treatment of certain human cancers.

PMID:
17482130
PMCID:
PMC2564847
DOI:
10.1016/j.ccr.2007.02.025
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center